A Phase Ia Dose Escalation, Randomized, Double-Blinded, and Placebo- Controlled Clinical Study of Single Dose and Multiple Doses of XW001 Inhalation Solution in Healthy Adult Subjects
Latest Information Update: 13 Mar 2023
At a glance
- Drugs XW 001 (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions; First in man
- Sponsors Sciwind Biosciences
Most Recent Events
- 13 Dec 2022 New trial record